An Analysis of Strategic Treatment Interruptions During Imatinib Treatment of Chronic Myelogenous Leukemia With Imatinib-Resistant Mutations

Mathematical Biosciences - United States
doi 10.1016/j.mbs.2015.01.011
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Characteristics of Dasatinib- And Imatinib-Resistant Chronic Myelogenous Leukemia Cells

Clinical Cancer Research
Cancer ResearchOncology
2008English

Suboptimal Responses to Imatinib in Chronic Myelogenous Leukemia

Clinical Journal of Oncology Nursing
Oncology
2009English

Dasatinib in the Treatment of Imatinib Refractory Chronic Myeloid Leukemia

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2009English

Increased Cortical Bone Mineralization in Imatinib Treated Patients With Chronic Myelogenous Leukemia

Haematologica
Hematology
2008English

Treatment of Resistant Chronic Myelogenous Leukemia With Ponatinib: One Centre Experience

Hematology & blood transfusion: interdepartamental collection
2016English

Characteristics of the TCR Vβ Repertoire in Imatinib-Resistant Chronic Myeloid Leukemia Patients With ABL Mutations

Science China Life Sciences
GeneticsMolecular BiologyEnvironmental ScienceBiochemistryBiological SciencesAgricultural
2015English

Treatment Options for Patients With Chronic Myeloid Leukemia Who Are Resistant to or Unable to Tolerate Imatinib

Clinical Therapeutics
Pharmacology
2010English

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Cancer Research
Cancer ResearchOncology
2004English

Epstein-Barr Virus-Associated Lymphoproliferative Disease During Imatinib Mesylate Treatment for Chronic Myeloid Leukemia

Haematologica
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy